Paladin buys struggling CNS company Allon Therapeutics for $Cdn900k
Paladin Labs Inc. (builds its portfolio through in-licensing) has paid $Cdn900k ($866k) in cash to acquire formerly publicly traded Allon Therapeutics Inc. (had been developing CNS candidates). The transaction was conducted as a result of Allon’s proposed bankruptcy filing in Canada, and the company will immediately disperse the funds it receives to its creditors.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com